Clinical Trial Update: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing trabectedin (ET-743) to clinician's choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers with BRCA mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Neoplasms
• Peritoneal Cancer

Drugs mentioned

• Trabectedin (trabectedin)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Ovarian Neoplasms | Phase 3 | Status: COMPLETED